Cargando…

A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)

Background: Systemic immune-inflammation index (SII) is calculated by multiplying the neutrophil-lymphocyte ratio (NLR) and the platelet count. In this study, we aimed to investigate the difference of SII and other inflammatory markers in patients with acne vulgaris compared to healthy controls and...

Descripción completa

Detalles Bibliográficos
Autores principales: TURAN, ÇAĞRI, METIN, NURCAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical University Publishing House Craiova 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289579/
https://www.ncbi.nlm.nih.gov/pubmed/35911945
http://dx.doi.org/10.12865/CHSJ.48.01.09
_version_ 1784748698704543744
author TURAN, ÇAĞRI
METIN, NURCAN
author_facet TURAN, ÇAĞRI
METIN, NURCAN
author_sort TURAN, ÇAĞRI
collection PubMed
description Background: Systemic immune-inflammation index (SII) is calculated by multiplying the neutrophil-lymphocyte ratio (NLR) and the platelet count. In this study, we aimed to investigate the difference of SII and other inflammatory markers in patients with acne vulgaris compared to healthy controls and themselves after Oral isotretinoin (ISO) treatment. Materials and methods: In this study 190 patients with severe acne vulgaris who received at least 3 months of ISO treatment (0.5-1mg/kg/day) and 66 healthy individuals were evaluated. Hemoglobin, neutrophil, lymphocyte, monocyte, and platelet counts, mean platelet volume (MPV), Plateletcrit (PCT), NLR, platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and SII were analyzed. Results: Before ISO treatment, patients with moderate-to-severe acne vulgaris had significantly higher neutrophil counts and SII levels than healthy controls (p=0.036, p=0.028; respectively). In the third month of ISO treatment, both neutrophil count and SII level were similar to healthy control (p=0.376, p=0.379; respectively). In the follow-up of patients using ISO, a significant decrease was observed especially in SII levels (p=0.037). Although the lymphocyte count was not significantly different from the control group before treatment, it increased significantly after ISO and was significantly higher than both the control and pretreatment period (p=0.134, P=0.026, p=0.017; respectively). Although NLR was not different from control in the pre- and post-treatment period, the change in neutrophil and lymphocyte counts after treatment caused a statistically significant decrease in NLR (p=0.682, p=0.289, p=0.043; respectively). Conclusions: We believe that SII is a more useful parameter as an indicator of the anti-inflammatory effect of isotretinoin.
format Online
Article
Text
id pubmed-9289579
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Medical University Publishing House Craiova
record_format MEDLINE/PubMed
spelling pubmed-92895792022-07-28 A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII) TURAN, ÇAĞRI METIN, NURCAN Curr Health Sci J Original Paper Background: Systemic immune-inflammation index (SII) is calculated by multiplying the neutrophil-lymphocyte ratio (NLR) and the platelet count. In this study, we aimed to investigate the difference of SII and other inflammatory markers in patients with acne vulgaris compared to healthy controls and themselves after Oral isotretinoin (ISO) treatment. Materials and methods: In this study 190 patients with severe acne vulgaris who received at least 3 months of ISO treatment (0.5-1mg/kg/day) and 66 healthy individuals were evaluated. Hemoglobin, neutrophil, lymphocyte, monocyte, and platelet counts, mean platelet volume (MPV), Plateletcrit (PCT), NLR, platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and SII were analyzed. Results: Before ISO treatment, patients with moderate-to-severe acne vulgaris had significantly higher neutrophil counts and SII levels than healthy controls (p=0.036, p=0.028; respectively). In the third month of ISO treatment, both neutrophil count and SII level were similar to healthy control (p=0.376, p=0.379; respectively). In the follow-up of patients using ISO, a significant decrease was observed especially in SII levels (p=0.037). Although the lymphocyte count was not significantly different from the control group before treatment, it increased significantly after ISO and was significantly higher than both the control and pretreatment period (p=0.134, P=0.026, p=0.017; respectively). Although NLR was not different from control in the pre- and post-treatment period, the change in neutrophil and lymphocyte counts after treatment caused a statistically significant decrease in NLR (p=0.682, p=0.289, p=0.043; respectively). Conclusions: We believe that SII is a more useful parameter as an indicator of the anti-inflammatory effect of isotretinoin. Medical University Publishing House Craiova 2022 2022-03-31 /pmc/articles/PMC9289579/ /pubmed/35911945 http://dx.doi.org/10.12865/CHSJ.48.01.09 Text en Copyright © 2014, Medical University Publishing House Craiova https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
spellingShingle Original Paper
TURAN, ÇAĞRI
METIN, NURCAN
A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)
title A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)
title_full A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)
title_fullStr A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)
title_full_unstemmed A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)
title_short A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII)
title_sort novel inflammatory marker in the follow-up of moderate-to-severe acne vulgaris administered isotretinoin: systemic immune-inflammation index (sii)
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289579/
https://www.ncbi.nlm.nih.gov/pubmed/35911945
http://dx.doi.org/10.12865/CHSJ.48.01.09
work_keys_str_mv AT turancagri anovelinflammatorymarkerinthefollowupofmoderatetosevereacnevulgarisadministeredisotretinoinsystemicimmuneinflammationindexsii
AT metinnurcan anovelinflammatorymarkerinthefollowupofmoderatetosevereacnevulgarisadministeredisotretinoinsystemicimmuneinflammationindexsii
AT turancagri novelinflammatorymarkerinthefollowupofmoderatetosevereacnevulgarisadministeredisotretinoinsystemicimmuneinflammationindexsii
AT metinnurcan novelinflammatorymarkerinthefollowupofmoderatetosevereacnevulgarisadministeredisotretinoinsystemicimmuneinflammationindexsii